Infliximab, a monoclonal anti-tumor necrosis factor-α (TNF-α) antibody, is recommended as the first-line immunosuppressive drug for steroid-refractory CIP. This evidence concerns the gene TNF and hereditary sensory and autonomic neuropathy.